ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes

In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib. Key topics covered in this episode: The PARADIGM trial and its impact on AML treatment strategies Real-world evidence on shortened venetoclax dosing The role of menin inhibitors in combination therapies Patient-reported outcomes and quality of life with asciminib in CML Tune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.  Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights! #OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology